QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Eitemau Tebyg

• Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
  gan: Santos, Nancy Dos, et al.
  Cyhoeddwyd: (2007)
• Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267
  gan: Kalra, Jessica, et al.
  Cyhoeddwyd: (2011)
• Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1
  gan: Kalra, J, et al.
  Cyhoeddwyd: (2010)
• Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes
  gan: Wu, Chuanyue, et al.
  Cyhoeddwyd: (2001)
• The Small Molecule Inhibitor QLT0267 Radiosensitizes Squamous Cell Carcinoma Cells of the Head and Neck
  gan: Eke, Iris, et al.
  Cyhoeddwyd: (2009)